An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer.

Aged Biomarkers, Tumor / genetics Class I Phosphatidylinositol 3-Kinases / genetics Colorectal Neoplasms / genetics Cyclooxygenase 2 / genetics DNA Methylation / genetics Female Humans Long Interspersed Nucleotide Elements / genetics Lymphocyte Count Lymphocytes / pathology Lymphocytes, Tumor-Infiltrating / metabolism Male Microsatellite Instability Middle Aged Prognosis Proportional Hazards Models Proto-Oncogene Proteins B-raf / genetics Proto-Oncogene Proteins p21(ras) / genetics beta Catenin / genetics

Journal

British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635

Informations de publication

Date de publication:
04 2020
Historique:
received: 27 10 2019
accepted: 19 02 2020
revised: 12 02 2020
pubmed: 12 3 2020
medline: 23 12 2020
entrez: 12 3 2020
Statut: ppublish

Résumé

Histological lymphocytic reaction is regarded as an independent prognostic marker in colorectal cancer. Considering the lack of adequate statistical power, adjustment for selection bias and comprehensive tumour molecular data in most previous studies, we investigated the strengths of the prognostic associations of lymphocytic reaction in colorectal carcinoma by utilising an integrative database of two prospective cohort studies. We examined Crohn's-like reaction, intratumoural periglandular reaction, peritumoural reaction and tumour-infiltrating lymphocytes in 1465 colorectal carcinoma cases. Using covariate data of 4420 colorectal cancer cases in total, inverse probability-weighted Cox proportional hazard regression model was used to control for selection bias (due to tissue availability) and potential confounders, including stage, MSI status, LINE-1 methylation, PTGS2 and CTNNB1 expression, KRAS, BRAF and PIK3CA mutations, and tumour neoantigen load. Higher levels of each lymphocytic reaction component were associated with better colorectal cancer-specific survival (P The four lymphocytic reaction components are prognostic biomarkers in colorectal carcinoma.

Sections du résumé

BACKGROUND
Histological lymphocytic reaction is regarded as an independent prognostic marker in colorectal cancer. Considering the lack of adequate statistical power, adjustment for selection bias and comprehensive tumour molecular data in most previous studies, we investigated the strengths of the prognostic associations of lymphocytic reaction in colorectal carcinoma by utilising an integrative database of two prospective cohort studies.
METHODS
We examined Crohn's-like reaction, intratumoural periglandular reaction, peritumoural reaction and tumour-infiltrating lymphocytes in 1465 colorectal carcinoma cases. Using covariate data of 4420 colorectal cancer cases in total, inverse probability-weighted Cox proportional hazard regression model was used to control for selection bias (due to tissue availability) and potential confounders, including stage, MSI status, LINE-1 methylation, PTGS2 and CTNNB1 expression, KRAS, BRAF and PIK3CA mutations, and tumour neoantigen load.
RESULTS
Higher levels of each lymphocytic reaction component were associated with better colorectal cancer-specific survival (P
CONCLUSIONS
The four lymphocytic reaction components are prognostic biomarkers in colorectal carcinoma.

Identifiants

DOI: 10.1038/s41416-020-0780-3 PMID: 32157241 PMC: PMC7188805
pubmed: 32157241
doi: 10.1038/s41416-020-0780-3
pii: 10.1038/s41416-020-0780-3
pmc: PMC7188805
doi:

Substances chimiques

Biomarkers, Tumor 0
CTNNB1 protein, human 0
KRAS protein, human 0
beta Catenin 0
Cyclooxygenase 2 EC 1.14.99.1
PTGS2 protein, human EC 1.14.99.1
Class I Phosphatidylinositol 3-Kinases EC 2.7.1.137
PIK3CA protein, human EC 2.7.1.137
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1367-1377

Subventions

Organisme : NIDDK NIH HHS
ID : K24 DK098311
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA137178
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA118553
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA127003
Pays : United States
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : JP2017-775
Pays : International
Organisme : NCI NIH HHS
ID : R35 CA197735
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA188126
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA169141
Pays : United States
Organisme : Cancer Research UK (CRUK)
ID : UK C10674/A27140
Pays : International
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA055075
Pays : United States
Organisme : Dana-Farber/Harvard Cancer Center (DF/HCC)
ID : 2016-02
Pays : International
Organisme : Cancer Research UK
ID : C10674/A27140
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : K07 CA190673
Pays : United States
Organisme : American Association for Cancer Research (American Association for Cancer Research, Inc.)
ID : SU2C-AACR-DT22-17
Pays : International
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : JP201860083
Pays : International
Organisme : NCI NIH HHS
ID : R01 CA151993
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States

Références

Giraldo, N. A., Sanchez-Salas, R., Peske, J. D., Vano, Y., Becht, E., Petitprez, F. et al. The clinical role of the TME in solid cancer. Br. J. Cancer 120, 45–53 (2019).
pubmed: 30413828 doi: 10.1038/s41416-018-0327-z
Ogino, S., Nowak, J. A., Hamada, T., Phipps, A. I., Peters, U., Milner, D. A. Jr. et al. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. Gut 67, 1168–1180 (2018).
pubmed: 29437869 doi: 10.1136/gutjnl-2017-315537
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B. et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat. Rev. Cancer 17, 286–301 (2017).
pubmed: 28338065 doi: 10.1038/nrc.2017.17
Barnes, T. A. & Amir, E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br. J. Cancer 117, 451–460 (2017).
pubmed: 28704840 pmcid: 5558691 doi: 10.1038/bjc.2017.220
Ogino, S., Nosho, K., Irahara, N., Meyerhardt, J. A., Baba, Y., Shima, K. et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin. Cancer Res. 15, 6412–6420 (2009).
pubmed: 19825961 pmcid: 2771425 doi: 10.1158/1078-0432.CCR-09-1438
Mlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D. et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44, 698–711 (2016).
pubmed: 26982367 doi: 10.1016/j.immuni.2016.02.025
Rozek, L. S., Schmit, S. L., Greenson, J. K., Tomsho, L. P., Rennert, H. S., Rennert, G. et al. Tumor-infiltrating lymphocytes, Crohn’s-like lymphoid reaction, and survival from colorectal cancer. J. Natl Cancer Inst. 108, djw027 (2016).
Vayrynen, J. P., Sajanti, S. A., Klintrup, K., Makela, J., Herzig, K. H., Karttunen, T. J. et al. Characteristics and significance of colorectal cancer associated lymphoid reaction. Int J. Cancer 134, 2126–2135 (2014).
pubmed: 24154855 doi: 10.1002/ijc.28533
Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R. et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 17, 1206 (2016).
pubmed: 27760322 pmcid: 5638785 doi: 10.1016/j.celrep.2016.10.009
Brown, S. D., Warren, R. L., Gibb, E. A., Martin, S. D., Spinelli, J. J., Nelson, B. H. et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 24, 743–750 (2014).
pubmed: 24782321 pmcid: 4009604 doi: 10.1101/gr.165985.113
Zelenay, S., van der Veen, A. G., Bottcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015).
pubmed: 26343581 pmcid: 4597191 doi: 10.1016/j.cell.2015.08.015
Grasso, C. S., Giannakis, M., Wells, D. K., Hamada, T., Mu, X. J., Quist, M. et al. Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov. 8, 730–749 (2018).
pubmed: 29510987 pmcid: 5984687 doi: 10.1158/2159-8290.CD-17-1327
Advani, S. M., Advani, P., DeSantis, S. M., Brown, D., VonVille, H. M., Lam, M. et al. Clinical, pathological, and molecular characteristics of CpG Island methylator phenotype in colorectal cancer: a systematic review and meta-analysis. Transl. Oncol. 11, 1188–1201 (2018).
pubmed: 30071442 pmcid: 6080640 doi: 10.1016/j.tranon.2018.07.008
Baba, Y., Huttenhower, C., Nosho, K., Tanaka, N., Shima, K., Hazra, A. et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol. Cancer 9, 125 (2010).
pubmed: 20507599 pmcid: 2892454 doi: 10.1186/1476-4598-9-125
Ogino, S., Nosho, K., Kirkner, G. J., Kawasaki, T., Meyerhardt, J. A., Loda, M. et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58, 90–96 (2009).
pubmed: 18832519 doi: 10.1136/gut.2008.155473
Ogino, S., Kirkner, G. J., Nosho, K., Irahara, N., Kure, S., Shima, K. et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin. Cancer Res. 14, 8221–8227 (2008).
pubmed: 19088039 pmcid: 2679582 doi: 10.1158/1078-0432.CCR-08-1841
Morikawa, T., Kuchiba, A., Yamauchi, M., Meyerhardt, J. A., Shima, K., Nosho, K. et al. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. J. Am. Med. Assoc. 305, 1685–1694 (2011).
doi: 10.1001/jama.2011.513
Ogino, S., Nosho, K., Kirkner, G. J., Kawasaki, T., Chan, A. T., Schernhammer, E. S. et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J. Natl Cancer Inst. 100, 1734–1738 (2008).
pubmed: 19033568 pmcid: 2639290 doi: 10.1093/jnci/djn359
Liu, L., Nevo, D., Nishihara, R., Cao, Y., Song, M., Twombly, T. S. et al. Utility of inverse probability weighting in molecular pathological epidemiology. Eur. J. Epidemiol. 33, 381–392 (2018).
pubmed: 29264788 doi: 10.1007/s10654-017-0346-8
Hamada, T., Cao, Y., Qian, Z. R., Masugi, Y., Nowak, J. A., Yang, J. et al. Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status. J. Clin. Oncol. 35, 1836–1844 (2017).
pubmed: 28406723 pmcid: 5455595 doi: 10.1200/JCO.2016.70.7547
Seaman, S. R. & White, I. R. Review of inverse probability weighting for dealing with missing data. Stat. Methods Med. Res. 22, 278–295 (2013).
pubmed: 21220355 doi: 10.1177/0962280210395740
Sheikh, K. Investigation of selection bias using inverse probability weighting. Eur. J. Epidemiol. 22, 349–350 (2007).
pubmed: 17484025 doi: 10.1007/s10654-007-9131-4
Nishihara, R., Wu, K., Lochhead, P., Morikawa, T., Liao, X., Qian, Z. R. et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N. Engl. J. Med. 369, 1095–1105 (2013).
pubmed: 24047059 doi: 10.1056/NEJMoa1301969
Yamauchi, M., Morikawa, T., Kuchiba, A., Imamura, Y., Qian, Z. R., Nishihara, R. et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61, 847–854 (2012).
pubmed: 22427238 doi: 10.1136/gutjnl-2011-300865
Kosumi, K., Hamada, T., Koh, H., Borowsky, J., Bullman, S., Twombly, T. S. et al. The amount of bifidobacterium genus in colorectal carcinoma tissue in relation to tumor characteristics and clinical outcome. Am. J. Pathol. 188, 2839–2852 (2018).
pubmed: 30243655 pmcid: 6284552 doi: 10.1016/j.ajpath.2018.08.015
Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M. et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 367, 1596–1606 (2012).
pubmed: 23094721 pmcid: 3532946 doi: 10.1056/NEJMoa1207756
Nosho, K., Irahara, N., Shima, K., Kure, S., Kirkner, G. J., Schernhammer, E. S. et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 3, e3698 (2008).
pubmed: 19002263 pmcid: 2579485 doi: 10.1371/journal.pone.0003698
Irahara, N., Nosho, K., Baba, Y., Shima, K., Lindeman, N. I., Hazra, A. et al. Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. J. Mol. Diagn. 12, 177–183 (2010).
pubmed: 20093385 pmcid: 2871724 doi: 10.2353/jmoldx.2010.090106
Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R. et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 15, 857–865 (2016).
pubmed: 27149842 pmcid: 4850357 doi: 10.1016/j.celrep.2016.03.075
Nielsen, M. & Andreatta, M. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med. 8, 33 (2016).
pubmed: 27029192 pmcid: 4812631 doi: 10.1186/s13073-016-0288-x
Chan, A. T., Ogino, S. & Fuchs, C. S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 356, 2131–2142 (2007).
pubmed: 17522398 doi: 10.1056/NEJMoa067208
Masugi, Y., Nishihara, R., Yang, J., Mima, K., da Silva, A., Shi, Y. et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut 66, 1463–1473 (2017).
pubmed: 27196573 doi: 10.1136/gutjnl-2016-311421
Benjamin, D. J., Berger, J. O., Johannesson, M., Nosek, B. A., Wagenmakers, E. J., Berk, R. et al. Redefine statistical significance. Nat. Hum. Behav. 2, 6–10 (2018).
pubmed: 30980045 doi: 10.1038/s41562-017-0189-z
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
pubmed: 17008531 doi: 10.1126/science.1129139
Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C. et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J. Pathol. 232, 199–209 (2014).
pubmed: 24122236 doi: 10.1002/path.4287
Pages, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F. S., Bifulco, C. et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391, 2128–2139 (2018).
pubmed: 29754777 doi: 10.1016/S0140-6736(18)30789-X
Pages, F., Kirilovsky, A., Mlecnik, B., Asslaber, M., Tosolini, M., Bindea, G. et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 27, 5944–5951 (2009).
pubmed: 19858404 doi: 10.1200/JCO.2008.19.6147
Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
pubmed: 29567705 pmcid: 7391259 doi: 10.1126/science.aar4060
Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E. et al. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy. Cancer Treat. Rev. 76, 22–32 (2019).
pubmed: 31079031 doi: 10.1016/j.ctrv.2019.04.003
Kather, J. N. & Halama, N. Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer. Br. J. Cancer 120, 871–882 (2019).
pubmed: 30936499 pmcid: 6734657 doi: 10.1038/s41416-019-0441-6
Kudryavtseva, A. V., Lipatova, A. V., Zaretsky, A. R., Moskalev, A. A., Fedorova, M. S., Rasskazova, A. S. et al. Important molecular genetic markers of colorectal cancer. Oncotarget 7, 53959–53983 (2016).
pubmed: 27276710 pmcid: 5288236 doi: 10.18632/oncotarget.9796
Punt, C. J., Koopman, M. & Vermeulen, L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat. Rev. Clin. Oncol. 14, 235–246 (2017).
pubmed: 27922044 doi: 10.1038/nrclinonc.2016.171
Becht, E., de Reynies, A., Giraldo, N. A., Pilati, C., Buttard, B., Lacroix, L. et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin. Cancer Res. 22, 4057–4066 (2016).
pubmed: 26994146 doi: 10.1158/1078-0432.CCR-15-2879
Taube, J. M., Galon, J., Sholl, L. M., Rodig, S. J., Cottrell, T. R., Giraldo, N. A. et al. Implications of the tumor immune microenvironment for staging and therapeutics. Mod. Pathol. 31, 214–234 (2018).
pubmed: 29192647 doi: 10.1038/modpathol.2017.156
Wirth, T. C. & Kuhnel, F. Neoantigen targeting-dawn of a new era in cancer immunotherapy? Front. Immunol. 8, 1848 (2017).
pubmed: 29312332 pmcid: 5742119 doi: 10.3389/fimmu.2017.01848
Nosho, K., Baba, Y., Tanaka, N., Shima, K., Hayashi, M., Meyerhardt, J. A. et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J. Pathol. 222, 350–366 (2010).
pubmed: 20927778 pmcid: 3033700 doi: 10.1002/path.2774
Marisa, L., Svrcek, M., Collura, A., Becht, E., Cervera, P., Wanherdrick, K. et al. The balance between cytotoxic T-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors. J. Natl Cancer Inst. 110, 68–77 (2018).
Hu, G. & Wang, S. Tumor-infiltrating CD45RO(+) memory T lymphocytes predict favorable clinical outcome in solid tumors. Sci. Rep. 7, 10376 (2017).
pubmed: 28871164 pmcid: 5583330 doi: 10.1038/s41598-017-11122-2
Park, J. H., van Wyk, H., Roxburgh, C. S. D., Horgan, P. G., Edwards, J. & McMillan, D. C. Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer. Br. J. Cancer 116, 1444–1450 (2017).
pubmed: 28427085 pmcid: 5520088 doi: 10.1038/bjc.2017.108
Dirschmid, K., Sterlacci, W., Woll, E., Tschann, P., Rhomberg, M. & Offner, F. Incidence of extramural venous invasion in colorectal carcinoma as determined at the invasive tumor front and its prognostic impact. Hum. Pathol. 86, 102–107 (2019).
pubmed: 30571994 doi: 10.1016/j.humpath.2018.11.031
Lang-Schwarz, C., Melcher, B., Haumaier, F., Lang-Schwarz, K., Rupprecht, T., Vieth, M. et al. Budding and tumor-infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups. Hum. Pathol. 79, 160–167 (2018).
pubmed: 29787819 doi: 10.1016/j.humpath.2018.05.010
Hamada, T., Nowak, J. A., Milner, D. A. Jr., Song, M. & Ogino, S. Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms. J. Pathol. 247, 615–628 (2019).
pubmed: 30632609 pmcid: 6509405 doi: 10.1002/path.5236

Auteurs

Koichiro Haruki (K)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Keisuke Kosumi (K)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Peilong Li (P)

Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, China.

Kota Arima (K)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Juha P Väyrynen (JP)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
ORCID: 0000-0002-8683-2996

Mai Chan Lau (MC)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Tyler S Twombly (TS)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Tsuyoshi Hamada (T)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Jonathan N Glickman (JN)

Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MS, USA.

Kenji Fujiyoshi (K)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Yang Chen (Y)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Chunxia Du (C)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Chunguang Guo (C)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Sara A Väyrynen (SA)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

Andressa Dias Costa (A)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

Mingyang Song (M)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.

Andrew T Chan (AT)

Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Jeffrey A Meyerhardt (JA)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

Reiko Nishihara (R)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Charles S Fuchs (CS)

Yale Cancer Center, New Haven, CT, USA.
Department of Medicine, Yale School of Medicine, New Haven, CT, USA.
Smilow Cancer Hospital, New Haven, CT, USA.

Li Liu (L)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Department of Epidemiology and Biostatistics, and the Ministry of Education Key Lab of Environment and Health, School of Public Health, Huazhong University of Science and Technology, Wuhan, China.

Xuehong Zhang (X)

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Kana Wu (K)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Marios Giannakis (M)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Jonathan A Nowak (JA)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Shuji Ogino (S)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. sogino@bwh.harvard.edu.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. sogino@bwh.harvard.edu.
Broad Institute of MIT and Harvard, Cambridge, MA, USA. sogino@bwh.harvard.edu.
Cancer Immunology and Cancer Epidemiology Programs, Dana-Farber Harvard Cancer Center, Boston, MA, USA. sogino@bwh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › An integrated analysis of lymphocytic...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › An integrated analysis of lymphocytic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Phosphatidylinositol 3-kinases › Phosphatidylinositol-4-phosphate 3-kinase › Phosphatidylinositol 3-kinases de classe I › An integrated analysis of lymphocytic...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies du rectum › Tumeurs colorectales › An integrated analysis of lymphocytic...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Complexes multienzymatiques › Cyclooxygenase 2 › An integrated analysis of lymphocytic...
questionsmedicales.fr › Phénomènes génétiques › Méthylation de l'ADN › An integrated analysis of lymphocytic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › An integrated analysis of lymphocytic...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Séquences répétées dispersées › Rétroéléments › Éléments LINE › An integrated analysis of lymphocytic...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiogiques du sang › Hémogramme › Numération des leucocytes › Numération des lymphocytes › An integrated analysis of lymphocytic...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › An integrated analysis of lymphocytic...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes TIL › An integrated analysis of lymphocytic...
questionsmedicales.fr › Phénomènes génétiques › Instabilité du génome › Instabilité des microsatellites › An integrated analysis of lymphocytic...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › An integrated analysis of lymphocytic...
questionsmedicales.fr › Diagnostic › Pronostic › An integrated analysis of lymphocytic...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Modèles des risques proportionnels › An integrated analysis of lymphocytic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Kinases raf › Protéines proto-oncogènes B-raf › An integrated analysis of lymphocytic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes p21(ras) › An integrated analysis of lymphocytic...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › bêta-Caténine › An integrated analysis of lymphocytic...